ClinicalTrials.gg
RecruitingNCT07390435FACTORUpdated Nov 12, 2026

Feasibility and Acceptability of Collecting Sociodemographic Data in CCTG Trials

An observational study in Cancer, sponsored by Canadian Cancer Trials Group. Recruiting at 16 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Canadian Cancer Trials Group · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Nov 12, 2026Site recruiting status changed2 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Ecologic or community
Time perspective
Other
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Study summary

This study is being done to answer the following question: Are patients on a clinical trial willing to provide answers to questions about their social, economic, and environmental factors-sometimes called social determinants of health-which affect people's health experiences and access to care. These factors may include income, education, employment, housing, social supports, and experiences with discrimination or stress. Participation will help researchers better understand barriers to participating in clinical trials and access to health care.

Read the detailed description

It is anticipated that 1000 people will take part in this study. Participation in this study will only take about 10 minutes or less. Participants who choose to take part in this study will be asked to fill out a form with questions in English or French about the non-medical factors that influence health. This includes asking about the conditions and places in which the participant lives, learns, works, and plays. Participants will also be asked how they feel about answering these questions. Researchers will use this information to better understand who participates in clinical trials.

02

Conditions studied

  • Cancer

Browse trials for

03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 200 across 2,644 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Canadian Cancer Trials Group is the lead sponsor of 93 studies on the registry; 29 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study is designed to include participants who have consented to a CCTG clinical trial. If a patient consents to a CCTG trial but does not enroll, they will remain eligible for SC.32S.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (≥18 years) who are either:

    • Currently being screened and consented to a CCTG trial (prospective).
    • Already enrolled in an ongoing CCTG trial and still under follow-up (retrospective).

Exclusion criteria

Exclusion Criteria:

  • Participants already enrolled or expected to enroll in a CCTG trial that is also collecting the SDoH Questionnaire.
05

Study design

Observational model
Ecologic or community
Time perspective
Other
Enrollment
1,000 participants (estimated)
Patient registry
No

Interventions

  • OtherSocial Determinants of Health Questionnaire

    This study will use a standardized SDoH Questionnaire to collect the required sociodemographic data

06

What researchers measure

Primary outcomes

  1. To evaluate the feasibility of collecting comprehensive sociodemographic data via a standardized SDoH Questionnaire among participants being screened and consented to a CCTG trial and participants already enrolled in a CCTG trial

    Time frame: 12 months

Secondary outcomes

  1. To assess the acceptability of this SDoH questionnaire to participants.

    Time frame: 12 months

07

Study locations

16 of 16 sites recruiting
  • Arthur J.E. Child Comprehensive Cancer Centre
    Calgary, Alberta T2N 5G2, Canada
    Recruiting
    • Marc Kerba · Contact403 521-3164
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
    Recruiting
    • Ericka Wiebe · Contact780 432-8755
  • BCCA - Kelowna
    Kelowna, British Columbia V1Y 5L3, Canada
    Recruiting
    • Katie Jasper · Contact250 712-3900
  • BCCA - Prince George
    Prince George, British Columbia V2M 7E9, Canada
    Recruiting
    • Andre Gouveia · Contact
  • BCCA - Vancouver
    Vancouver, British Columbia V5Z 4E6, Canada
    Recruiting
    • Leah Lambert · Contact604 877-6000
  • BCCA - Victoria
    Victoria, British Columbia V8R 6V5, Canada
    Recruiting
    • Caroline Holloway · Contact250 519-5609
  • Regional Health Authority B, Zone 2
    Saint John, New Brunswick E2L 4L2, Canada
    Recruiting
    • Anthony J. Reiman · Contact506 648-6884
  • Juravinski Cancer Centre at Hamilton Health Sciences
    Hamilton, Ontario L8V 5C2, Canada
    Recruiting
    • Courtney Coschi · Contact
  • Kingston Health Sciences Centre
    Kingston, Ontario K7L 2V7, Canada
    Recruiting
    • April Swoboda · Contact613 544-2361
  • Ottawa Hospital Research Institute
    Ottawa, Ontario K1H 8L6, Canada
    Recruiting
    • Moira Rushton · Contact
  • Algoma District Cancer Program
    Sault Ste. Marie, Ontario P6B 0A8, Canada
    Recruiting
    • Silvana Spadafora · Contact705 759-3434
  • Odette Cancer Centre
    Toronto, Ontario M4N 3M5, Canada
    Recruiting
    • Amandeep Taggar · Contact416 480-6165
  • CHA-Hopital Du St-Sacrement
    Québec, Quebec G1S 4L8, Canada
    Recruiting
    • Claudya Morin · Contact418 682-7511
  • CIUSSS de l'Estrie - Centre hospitalier
    Sherbrooke, Quebec J1H 5N4, Canada
    Recruiting
    • Isabelle C. Gauthier · Contact819 346-1110
  • Allan Blair Cancer Centre
    Regina, Saskatchewan S4T 7T1, Canada
    Recruiting
    • Ayesha Bashir · Contact306 766-2691
  • Saskatoon Cancer Centre
    Saskatoon, Saskatchewan S7N 4H4, Canada
    Recruiting
    • Shahid Ahmed · Contact306 655-2710
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jan 2027, 8 months after the start.

Of 1,099 non-industry observational studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 227. This study's planned 8 months is below that.

Counting every sponsor, half of 1,247 studies reached it within 58 months; a quarter within 24 and three quarters within 210.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2026
First posted
Feb 5, 2026
StartActual
May 15, 2026
Primary completionEst.
Jan 31, 2027
CompletionEst.
Jun 30, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added. Juravinski Cancer Centre at Hamilton Health Sciences is now Recruiting
Show 2 added (2 Canada)
  • Algoma District Cancer Program · Sault Ste. Marie, Canada
  • CIUSSS de l'Estrie - Centre hospitalier · Sherbrooke, Canada
across 2 updates, Oct 14, 2026 – Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    1 site added
    Show site
    • CIUSSS de l'Estrie - Centre hospitalier · Sherbrooke, Canada
  2. Oct 14, 2026
    1 site added. Juravinski Cancer Centre at Hamilton Health Sciences is now Recruiting
    Show site
    • Algoma District Cancer Program · Sault Ste. Marie, Canada

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07390435
Lead sponsor
Canadian Cancer Trials Group
Responsible party
Sponsor
First posted
Feb 5, 2026
Start date
May 15, 2026
Primary completion
Jan 31, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Anna Johnson
Contact
ajohnson@ctg.queensu.ca
613-533-6430
Mariam Jafri
Contact
mjafri@ctg.queensu.ca
613-533-6430
Leah Lambert
study chair · BCCA - Vancouver Cancer Centre, Vancouver, BC Canada
Michael McKenzie
study chair · BCCA - Vancouver Cancer Centre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion